Graduate Medical Education
Research Journal
Volume 2

Issue 2

Article 5

December 2020

Neurolytic Celiac Plexus Blockade in Patients with Upper
Intraabdominal Malignancies: An Evidence-Based Narrative
Review
Kevin Wong
Desert Orthopedic Center

Apollo A. Stack
University of Nebraska Medical Center

Madhuri Are
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/gmerj
Part of the Higher Education Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Wong, K., Stack, A. A., , Are, M. Neurolytic Celiac Plexus Blockade in Patients with Upper Intraabdominal
Malignancies: An Evidence-Based Narrative Review. Graduate Medical Education Research Journal. 2020
Dec 09; 2(2).
https://digitalcommons.unmc.edu/gmerj/vol2/iss2/5

This Literature Review (Systematic or Meta-Analysis) is brought to you for free and open access by
DigitalCommons@UNMC. It has been accepted for inclusion in Graduate Medical Education Research Journal by
an authorized editor of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.
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Malignancies: An Evidence-Based Narrative Review
Abstract
Background: Cancer-related abdominal pain is a common symptom associated with upper intraabdominal carcinoma, especially in patients with advanced disease and it has posed a significant
therapeutic challenge to medical practitioners. Typically, cancer pain can be managed by following the
World Health Organization 3-step analgesic ladder. However, analgesic use of opioids, the mainstay
treatment for moderate-to-severe cancer-related pain, may be ineffective in a subset of cancer patients.
Escalation of dosage may be limited by opioid-induced side effects. The aim of this study was to review
the literature addressing the effect of neurolytic celiac plexus block (NCPB) on the palliation of pain
emanating from advanced upper intra-abdominal malignancies.
Methods: Electronic databases including Medline/PubMed, EMBASE, and Cochrane Library were
searched. Only studies with a high level of evidence were reviewed. These included prospective
randomized control studies, systematic reviews and meta-analyses. Further, references from included
articles were carefully reviewed for additional relevant trials.
Results: A total of 13 prospective randomized trials, 5 systematic reviews and meta-analyses, and one
Cochrane review article were found to meet eligibility criteria.
Conclusion: Neurolysis of the celiac/splanchnic plexus is an effective and safe therapeutic modality that
should be considered early for palliation of cancer-related pain in advanced upper intra-abdominal
malignancies. This is especially true for patients with intolerable opioid-induced adverse events and
painful symptoms resistant to oral analgesics.
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Abstract
Background: Cancer-related abdominal pain
is a common symptom associated with intraabdominal malignancies, especially in patients
with advanced disease and it has posed a
significant therapeutic challenge to medical
practitioners. Typically, cancer pain can be
managed by following the World Health
Organization three-step analgesic ladder.
However, the use of opioids, the mainstay
treatment for moderate-to-severe cancerrelated pain, may be ineffective in a subset of
cancer patients. Escalation of dosage may be
limited by opioid-induced side effects. The
aim of our study was to review the literature
addressing the effect of neurolytic celiac
plexus block (NCPB) on the palliation of
pain emanating from advanced upper intraabdominal malignancies.
Methods: Electronic databases including
Medline/PubMed, EMBASE, and Cochrane
Library were searched. Only studies with
a high level of evidence were reviewed.
These included prospective randomized
control studies, systematic reviews and
meta-analyses. Furthermore, references from
included articles were carefully reviewed for
additional relevant trials.
Results: A total of 13 prospective randomized
trials, five systematic reviews and metaanalyses, and one Cochrane review article
were found to meet eligibility criteria.
Conclusion: Neurolysis of the celiac/
splanchnic plexus is an effective and safe
therapeutic modality that should be considered
early for palliation of cancer-related pain in
advanced upper intra-abdominal malignancies.
This is especially true for patients with
intolerable opioid-induced adverse events and
painful symptoms resistant to oral analgesics.

Introduction
Despite recent advances in diagnostic and
therapeutic modalities, cancer remains as the
second leading cause of death in the U.S.1
Pain is a relatively common cause of cancerrelated disability and the leading contributor
to poor quality of life (QoL).2 About 25 to
40% of cancer patients reported dying in
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agony secondary to moderate-to-severe pain
in their final three days.3,4 With increased life
expectancy in cancer patients it is important to
prevent needless suffering through prompt and
effective pain control, as a significant number
of cancer victims bear a poor prognosis,
especially those with advance-staged disease.5
Thus, in 70 to 80% of patients with advanced
disease, and up to 90% of those with bone
metastases, ablative procedures including
neurolysis of the celiac/splanchnic plexus
should be sought to improve analgesic
outcomes.6
Pathophysiology of Cancer-Related Pain
Cancer-related pain can be classified
as nociceptive, neuropathic, or mixed.7
Nociceptive pain can be further classified as
somatic or visceral.7 Somatic pain is described
as a squeezing or sharp sensation that can
be localized as a focal point of tenderness.7
Stimulation of peripheral sensory neurons, or
nociceptors, by noxious stimuli from tumor
invasion or compression of adjacent somatic
structures leads to somatic pain.8,9 On the
contrary, visceral pain presents in a poorly
localized, diffuse pattern that is accompanied
by a deep pressure-like sensation.7,10 It
can be triggered by smooth muscle spasm,
distension of hollow viscus or organ capsule,
chemical irritation, stretching or twisting of
the mesentery as well as ischemic injury of
visceral organs.9 Regardless of whether the
source is visceral or somatic, most patients
respond favorably to traditional analgesics.
Effective control of cancer-related
neuropathic pain remains a challenge as the
outcome of standard treatment is relatively
unpredictable.11 Neuropathic pain may be
perceived as burning, tingling, shooting and/
or lancinating forms of sensation.7 Further,
difficulties associated with the management
of neuropathic pain may be multifaceted
involving peripheral and central sensitization,
neuroplasticity and modulation of the
nociceptive somatosensory pathway within
the central nervous system.12
Regardless, the mechanism of cancer-related
pain can be attributed to a multitude of
mechanical, inflammatory, neuropathic, and
ischemic factors due to tumor infiltration
of neural structures, direct compression

of adjacent tissues, peripheral neuropathy
from chemotherapy, plexopathy and fibrosis
from radiation therapy, and chronic postsurgical pain.9,13 Treatment of cancer-related
pain can be achieved through multiple
modalities including pharmacological,
chemoradiotherapy, palliative surgeries and
interventional pain therapies.
Pharmacological Management of Upper
Intraabdominal Malignancies
Traditionally, the mainstay of cancer-related
analgesia is opioid-based. However, there
is increasingly more evidence supporting a
multimodal therapeutic approach.11 In general,
70 to 90% of cancer-related pain can be
managed by following the three-step analgesic
ladder developed by the World Health
Organization in 1986.14 However, 10 to 20%
of advanced cancer patients, especially those
with neuropathic pain and bone metastases,
remain refractory to standard therapies.3,10,15
Despite a multimodal pharmacological
approach, patients with upper intraabdominal
malignancies frequently experience
excruciating pain during the course of their
illnesses and psychological distress at the
end of life.12 Neurolytic celiac plexus block
(NCPB) has been proposed as an alternative
to ameliorating pain in patients with advanced
upper intraabdominal malignancies.
Relationship between Cancer-Related Pain
and Survival
Pain frequently creates considerable distress
in cancer patients. The prevalence of pain
in cancer patients was alarmingly high, with
53% of cancer patients at all disease stages
reporting it.14 Given the tremendous advances
in cancer therapy, which have resulted in
better life-expectancy and increased long-term
survival, the number of individuals suffering
from cancer pain is bound to increase
substantially.
It has long been speculated that uncontrolled
pain may pose a negative impact on the
survival of cancer patients. Cancer-related
pain is postulated to promote tumor growth
and metastases through a complex interplay
of cellular pathways and consequently
shorten survival.16,17 Putative mechanisms
include attenuation of immune response via
inhibitory effect on natural killer (NK) cells,
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stimulation of mitogen-activated protein
kinase (MAPK) to facilitate tumor growth,
and chronic activation of mu-opioid receptors
(MOP-R) from increased level of endorphins
or frequent use of opioids.16,17 Elevated levels
of endorphins and exogenous use of opioids
are thought to be the predominant triggers
that facilitate these mechanisms, leading to
reprogramming of tumor cells and thereby
promoting tumorigenesis.16
Of note, systemic use of opioids has become
an integral part of providing high-quality
palliative care for cancer patients. However,
numerous in-vitro and in-vivo studies
have demonstrated a dual effect on cancer
survival associated with administering
systemic opioids.18 Several mechanisms
have been proposed, including tumor cell
proliferation due to imbalance of pro- and
anti-apoptotic enzymes, angiogenesis as a
result of modulation of vascular endothelial
growth factor (VEGF) signaling, metastasis
due to changes in matrix metalloproteinases
(MMP), as well as expression, activity
level, and neurogenic inflammation due to
changes in gene expression of inflammatory
cytokines and receptors.18 Together, these
studies have highlighted the diametrically
opposed potentials of opioids in promoting
or inhibiting tumor proliferation. Given this
duality, it is not surprising that the association
between opioid usage and survival in cancer
patients remains unclear. In addition, the
common nature of opioid-induced side effects
and concerns related to tolerance, dependence,
and aberrant drug-seeking behaviors have
persuaded many practitioners to seek
alternatives for effective palliation of cancer
pain.
Interventional techniques have been
advocated as safe and effective strategies
for palliation of cancer-related pain without
causing intolerable side effects. There is
accumulating evidence implicating perineural
invasion of tumor cells in the pathogenesis
of tumor growth and migration.16 Recent
evidence from a preclinical study in mouse
models of pancreatic ductal adenocarcinoma
demonstrated that early denervation of
peripheral sensory fibers using capsaicin
significantly delayed neoplastic growth and
prolonged median survival by 3.3 months (p =
0.001).19 Similar findings have been reported
in other animal models including vagal nerve
ablation in gastric cancers, sympathectomy in
prostate cancer, and denervation of the dorsal
cutaneous nerve in basal cell carcinoma.20,21,22
Taken together, these models support the
notion that early surgical or chemical
denervation such as NCPB may prevent
neoplastic development, progression, and
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metastasis, resulting in improved pain relief
and prolonging survival.
Neuroanatomy of the Celiac Plexus
The celiac plexus is an extensively
interconnected network of neural structures
within the sympathetic nervous system.
It is formed by paired celiac ganglia and
autonomic fibers.23 The celiac ganglia supply
nociceptive and sympathetic efferent outputs
via thoracic splanchnic nerves to the upper
abdominal viscera including pancreas,
gallbladder, diaphragm, liver, spleen, distal
esophagus, stomach, small bowel, ascending
and proximal transverse colon, adrenal glands,
kidneys, abdominal aorta and mesentery.24,25
Similarly, nociceptive inputs from visceral
organs carried by afferent fibers will pass
through the celiac ganglia, thoracic splanchnic
nerves, and sympathetic ganglia to reach the
spinal cord. Thoracic splanchnic nerve fibers
branch off the sympathetic trunk and descend
medially through the diaphragmatic crura
along the paravertebral border to synapse with
celiac ganglia.23 The paired celiac ganglia
lie medial to the adrenal glands and anterior
to the descending thoracoabdominal aorta
bilaterally at T12 and L1 vertebral levels
in the retroperitoneal space.23,26 Despite
considerable anatomical variability, the
greater and lesser splanchnic nerves most
frequently arise from T5 to T9 and T9 to
T12 ganglia, respectively; while the least
splanchnic nerves are formed by nerve roots
arising from T11 to T12 ganglia.23
Techniques of Celiac/Splanchnic Nerve Block
The percutaneous celiac/splanchnic nerve
block has been ubiquitously performed for
the management of both malignant and
non-malignant pain involving the upper
abdominal viscera. The classic approach to
blocking these afferent nociceptive impulses
is described as the posterior percutaneous
retrocrural technique.27 Several modifications
of this conventional approach have been
described, which include transcrural,28,29
transaortic,30 transdiscal,31 and anterior
approach.32,33 The diaphragmatic crura serves
as an important landmark for this nerve block.
Chemical denervation of the celiac plexus
can be achieved with either a transcrural or
transaortic approach; while blockade of the
splanchnic nerves can be accomplished with a
retrocrural approach.27,34
Traditionally, the nerve block was performed
blindly using anatomical landmarks. Trimble
et al. first reported successful relief of upper
abdominal malignant pain via blockade of
the celiac plexus in 1952.35,36 The concept of
fluoroscopy-guided celiac plexus block was
introduced by Bonica et al. in 1954.37 Clinical

application of other advanced imaging
modalities, such as computed tomography
(CT), endoscopic ultrasound (EUS), and
videoscopic thoracoscopy, have also become
increasingly common to improve needle
accuracy, increase patient safety, reduce
catastrophic complications and enhance block
efficacy. Successful blockade of the celiac
plexus has also been demonstrated via direct
injection of neurolytic agent during surgical
laparotomy.38,39,40,41
Posterior Approach
The patient is placed in prone position. A
20- or 22-gauge, 12 to 15 cm needle is placed
approximately 7.5 cm lateral to the midline
and caudal to the 12th rib on each side.42,43
The needles are advanced at a 45o angle with
a slight 15o cephalad direction toward the
coronal plane. Lateral redirection of the needle
by gradual increments is required upon bony
contact of the first lumbar vertebral body.
Once the needle has walked off the vertebral
body, the needle on the left side should be
advanced 1.5 to 2 cm until aortic pulsation
can be detected. The same is repeated on the
right side with the needle advancing into the
retrocrural space (Figure 1)44,45 Incomplete
sympathetic blockade of the celiac plexus may
occur with the classic retrocrural approach.
Penetration of a neurolytic agent through the
aortic hiatus in the diaphragm is mandatory,
as demonstrated by Moore et al. in 1981, with
needle placement posterior and cephalad to
the diaphragmatic crura.46
The classic retrocrural approach was
modified to a transcrural technique by Boas
and Singler.28,29,47 There is no difference in
terms of needle placement on the left side
(Figure 2). However, the needle placed on the
right side will be advanced slightly further,
about 2 to 3 cm, just enough to penetrate
ventrally through the right diaphragmatic
crura. Regardless of whether the approach
is retrocrural or transcrural, the laterality of
needle placement on each side prompted the
search for modified techniques including the
transdiscal and transaortic approaches (Figure
3A and B). Both techniques require only one
needle projecting directly toward the central
region of the celiac plexus, causing less
patient discomfort and tissue injury. Contrast
medium is used to confirm correct placement
of needles and adequate spreading around the
T12 and L1 vertebral bodies. A diagnostic
block of local anesthetic with epinephrine
should be performed prior to all sympathetic
neurolysis, consistent with usual standards for
regional nerve blocks.
Anterior Approach
A modification of the classical approach
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is the CT- or ultrasound-guided anterior
approach (Figures. 4 & 5). The intervention
is performed with the patient supine and
needle is inserted perpendicular to the skin
slightly left of midline around the epigastric
region at 1.5 cm below xiphoid process.48
The needle is advanced into the precrural
space immediately anterior to the abdominal
aorta located between the origins of the
celiac trunk and superior mesenteric artery.49
The possibility of tumor cell seeding in the
needle track should always be considered in
cancer patients following the trans-pancreatic
approach. Proper needle placement can be
confirmed by the spread of contrast within the
anterolateral aspect of diaphragmatic crura.49
The purpose of this paper is to review the
literature addressing the effect of neurolytic
celiac plexus block (NCPB) on the palliation
of pain emanating from advanced upper intraabdominal malignancies.

Materials and Methods
We conducted an electronic literature
search in the following databases: Medline/
PubMed, EMBASE, and Cochrane Library
without specific limitation on the year
of publication. A search of the available
literature was performed in November 2017,
with the assistance of a librarian, using search
terms that captured publications related to
cancer pain, efficacy, survival, quality of
life, celiac plexus, splanchnic nerve, nerve
block, neurolysis, neurolytic, denervation,
carcinoma, neoplasm, metastases, cancerrelated and tumor. The number of initial hits
from these search terms was over 10,000
articles and was further narrowed down to
only those that also included the terms celiac
plexus and/or splanchnic nerve. The authors
initially reviewed titles and abstracts to find
the most pertinent studies before full texts
were read to determine inclusion/exclusion.
Only prospective randomized control trials,
systematic reviews and meta-analyses were
considered for review. All articles written
in non-English language were excluded.
A secondary search of the bibliographies
and citations of all included articles was
performed to ensure inclusion of all relevant
articles.

Results
A total of six randomized controlled trials
(RCTs), one prospective randomized
uncontrolled trial, one prospective nonrandomized controlled trial, one Cochrane
review, and five systematic reviews and/
or meta-analyses were eligible for review
of the efficacy of NCPB. There were two
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Figure 1. Computed tomography showing proper positioning of spinal needle in the right retrocrural
space. [Reprinted by permission from the Rightslink service of CCC: Springer Nature, Abdominal
Imaging. CT-guided percutaneous neurolytic celiac plexus block technique. Wang PJ, Shang MY,
Qian Z et al. 2006.]

Figure 2. Computed tomography showing the transcrural technique with placement of spinal needle
tip just pass the left diaphragmatic crura. [Reprinted by permission from the Rightslink service of
CCC: Springer Nature, Abdominal Imaging. CT-guided percutaneous neurolytic celiac plexus block
technique. Wang PJ, Shang MY, Qian Z et al. 2006.]
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Figure 3. The A-P (A) and lateral (B) views demonstrating contrast spread in the retrocrural space with the unilateral, single-needle transdiscal approach.
[Computed tomography (CT) simulated fluoroscopy-guided transdiscal approach in transcrural celiac plexus block by Kong GY et al. Copyright 2013 by The
Korean Pain Society. Reprinted by permission under the terms of Creative Common License CC BY-NC 3.0]

Figure 5. Ultrasound-guided technique showing the celiac trunk (T) and abdominal aorta (A). Needle
tip is placed immediately anterior to the abdominal aorta (dark arrows) between the celiac trunk and
mesentery artery (S). [Coeliac plexus neurolysis for upper abdominal malignancies using an anterior
approach: review of the literature by Ghai A et al. Copyright 2015 by Medpharm Publications, NISC
(Pty) Ltd and Cogent, Taylor & Francis Group. Reprinted by permission under the terms of Creative
Common License CC BY-NC-ND 4.0
Figure 4. Computed tomography demonstrating
the transpancreatic approach with appropriate
spread of contrast immediately anterior to
the abdominal aorta along the celiac axis.
[Coeliac plexus neurolysis for upper abdominal
malignancies using an anterior approach: review
of the literature by Ghai A et al. Copyright 2015
by Medpharm Publications, NISC (Pty) Ltd and
Cogent, Taylor & Francis Group. Reprinted
by permission under the terms of Creative
Common License CC BY-NC-ND 4.0]
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prospective randomized studies that compared
the efficacy of celiac plexus block with
splanchnic nerve block. There were four
prospective studies related to the effect of
NCPB on QoL and five prospective studies
related to the effect of NCPB on survival
(Table 1). One RCT was found that detailed
different volumes of alcohol in celiac plexus
block. There was only one retrospective study
comparing the effectiveness of alcohol and
phenol in NCPB.

Discussion
Efficacy of Celiac/Splanchnic Plexus
Neurolysis Prospective Clinical Trials
Neurolytic blockade of the celiac plexus
was originally reported by Kappis in 1914.50
However, the first prospective randomized
control study was not published until 1992.51
Ischia and associates evaluated 61 patients
with unresectable pancreatic cancer who were
randomized to undergo one of the 3 posterior
percutaneous approaches to NCPB, namely,
transaortic, classic retrocrural, and bilateral
chemical splanchniectomy. They reported
abolition of cancer-related celiac pain in 75%
of patients immediately post-NCPB and up
to 67% of patients at the time of death (p <
0.01). Interestingly, they found that only 1024% of patients had complete pain relief from
NCPB alone at the time of death, but up to
80-90% when combined with other therapies,
suggesting the clinical significance of a
multimodal analgesic approach. The authors
concluded that there was no statistically
significant difference in efficacy, morbidity,
performance status, survival rate, and type of
recurrent or residual pain among these three
techniques.
A smaller RCT of 20 patients with advanced
pancreatic cancer was performed to
investigate the effectiveness of NCPB in
alleviating severe cancer-related pain.52 This
pilot study by Mercadante in 1993 compared
the effectiveness of NCPB to traditional
nonsteroidal anti-inflammatory drugs
(NSAIDs) and opioid treatment on cancerrelated pain relief. Overall, both NCPB and
systemic analgesic therapy (SAT) provided
statistically significant reductions in visual
analogue scale (VAS) pain scores and opioid
dosage requirements at all seven weekly
follow-up intervals up to the time of death.
The authors concluded that NCPB may be
more desirable than SAT because of less
opioid-induced side effects.
The largest single center, double-blinded RCT
by Lillemoe and colleagues provided highquality, level-one evidence.53 Among the 137
patients evaluated, chemical splanchniectomy
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with alcohol significantly reduced mean pain
scores at 2, 4, and 6 months, and within two
months of death, especially for those with
significant preoperative pain (p ≤ 0.05). Time
to rescue with NCPB was also substantially
longer in the NCPB group compared to the
SAT group (11.8 vs. four-months; p ≤ 0.05).
Despite improved mood and lower disability
scores in patients receiving alcohol, there was
no statistically significant difference between
the alcohol and saline group. Adverse events
were reportedly minor and self-limited.
Their findings support the efficacy and safety
of intraoperative alcohol splanchniectomy
in advanced pancreatic cancer patients for
attaining favorable outcomes, including
significantly lower mean pain scores, lower
analgesic consumption, longer duration of
pain relief, and lower incidence of significant
pain at death.
Kawamata et al. published a pilot RCT of
21 patients with pancreatic cancer in 1996,
highlighting the effect of NCPB on healthrelated QoL.54 Consistent with the outcomes
from previous studies, NCPB significantly
reduced VAS pain score during first four
weeks immediately after the procedure
compared to SAT (p < 0.05). Morphine
consumption was found to be substantially
reduced from week four to seven after NCPB
(p < 0.05).
In an RCT published in 1998, Polati et
al. performed NCPB in 24 patients who
had unresectable pancreatic cancer over a
two-year period.55 They found complete
pain relief within 24 – 48 hours after NCPB
in 75% of patients compared to merely
17% in SAT (p < 0.05). There was also a
significant reduction in diclofenac use, opioid
consumption, and drug-related adverse events
in patients with NCPB. Notably, the complete
abolition of pain was achieved in only one
patient with NCPB alone, but nine patients
when combined with SAT. This finding was
consistent with those reported by Ischia and
associates, supporting the clinical importance
of a multimodal analgesic therapy. Despite
favorable outcomes in the reduction of VAS
pain score and oral analgesic use within 24 –
48 hours of treatment, the long-term results
were not significantly different between the
two groups.
Wong et al. conducted a prospective, doubleblinded RCT evaluating the effect of NCPB
on pain relief and opioid consumption
involving 100 patients with unresectable
pancreatic cancer.56 Both NCPB and
SAT substantially reduced pain intensity
compared to baseline, with the NCPB group
demonstrating a significantly greater pain

reduction than the SAT group (53% vs. 27%,
p = 0.005). Sustained analgesic benefits of
NCPB lasted until the time of death. There
was a gradual increase in opioid usage due
to tumor progression. Contrary to previous
studies,52,54,55 there was no significant
difference in opioid consumption between
NCPB and control (p = 0.93).
Jain et al. reported similar outcomes in
100 consecutive patients with advanced
malignancies suffering from upper
abdominal pain or backache.57 These patients
demonstrated superior analgesic benefits from
NCPB compared to SAT, where the VAS
pain score was significantly lower at 7 and
30 days after NCPB (p = 0.03 and p = 0.005,
respectively). Consistent with most studies,
mean consumption of morphine was lowered
by 50% at the 30-day interval in the NCPB
group (p = 0.00), with 31% of these patients
requiring only non-opioid and other adjuncts
for pain relief. The major weakness of this
study was imposed by the limitation of a nonrandomized and non-blinded design.
The efficacy of CT-guided NCPB was
assessed in a randomized control trial
by Zhang et al. involving patients with
unresectable pancreatic cancer.58 All 56
patients who received either CT-guided NCPB
or SAT obtained significant reduction in VAS
pain score at 1, 7, 14, 30, 60, and 90 days
after treatment compared to baseline VAS
pain score (p < 0.01). A significant difference
in the reduction of VAS pain score between
the two groups was found at only 1, 7, and
14 days after treatment (p < 0.01). Morphine
requirement was also significantly lower in
patients with NCPB at 7, 14, 30, 60, and 90
days after treatment compared to patients with
SAT (p < 0.01). The authors concluded that
CT-guided NCPB with alcohol is effective
for treatment of intractable pancreatic cancer
pain.
Systematic Review and Meta-Analysis
Eisenberg and colleagues conducted the first
meta-analysis to assess the efficacy and safety
of NCPB in patients with intraabdominal
malignancies.59 This meta-analysis pooled all
data published in 21 retrospective studies, one
prospective study, and two RCTs from 1966 to
1993, which involved a total of 1145 patients
with either pancreatic (63%) or non-pancreatic
(37%) intraabdominal malignancies. The
authors found that NCPB provided both shortand long-term analgesic efficacy in 89% (95%
CI: 86.9-90.9) and 90.2% (95% CI: 77.9-96.3)
of patients, respectively. Importantly, 6 of
the 24 studies demonstrated either partial
or complete pain relief in 73% and 92% of
patients, respectively. The reasons underlying
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List of prospective studies evaluating the effect of neurolytic celiac/splanchnic plexus blockade on pain reduction, opioid consumption, quality of life, and/or
survival in patients with advanced intraabdominal malignancies.

Ischia et al.,
1992.51

Prospective,
randomized
study

Patients with
unresectable
pancreatic cancer
pain aged 39-73

61

Transaortic celiac
plexus block vs.
classic retrocrural
nerve block vs.
bilateral chemical
splanchniectomy

VAS pain
score, Arner
and Arner pain
classification,
performance
status,
survival, type
of recurrent or
residual pain

Transaortic – 30
ml of absolute
alcohol via each
needle; classic
retrocrural – 15 ml
of absolute alcohol
via each needle;
bilateral chemical
splanchniectomy
– 7 ml of absolute
alcohol via each
needle

There was no statistically significant difference in
efficacy and morbidity among the three-posterior
percutaneous NCPB. Success rate was reported
to be 70-80% immediately after procedure and
60-75% at the time of death.

Transient, minor complications
were self-limited, which
include diarrhea, dysesthesia,
reactive pleurisy, hiccoughing,
and hematuria. Orthostatic
hypotension was reported in all
three techniques but significantly
less likely with transaortic
approach. No operative mortality
was reported.

NCPB is an appropriate
percutaneous technique for
pain relief in patients with
pancreatic cancer.

Mercadante
et al., 199352.

Prospective,
randomized
study

Pancreatic cancer
patients with oneweek treatment
of NSAID and
opioid analgesic
therapy

20

NCPB vs. SAT

VAS pain
score, opioid
consumption

25 ml of 75%
alcohol bilaterally

There was significant reduction of baseline
VAS score in both treatment groups by the 8th
week or at the time of death. However, there
was no significant difference in VAS score
between the two treatment groups. Patients who
received celiac plexus block required less opioid
consumption for the following 8 weeks or up to
the time of death.

There was one case of prolonged
diarrhea requiring octreotide, two
cases of orthostatic hypotension
lasting 48 hours requiring
vasopressors, and one case of
back pain at the needle entry site.

NCPB is safe and reduces
opioid consumption for pain
control in pancreatic cancer
patients.

Lillemoe et
al., 199353.

Prospective,
randomized,
double-blinded,
placebocontrolled trial

Patients with
suspected
unresectable
pancreatic cancer

137

Chemical
splanchniectomy
with 50% alcohol
in saline vs. 0.9%
normal saline
injection during
surgical exploration

Pain, mood,
and disability
score, survival
rate

20 ml of 50%
alcohol bilaterally

Intraoperative chemical splanchniectomy with
alcohol resulted in significant improvement in
mean pain score at 2-, 4-, and 6-month, and final
assessment within 2 months of death compared
to control group. Patients who received alcohol
treatment had significantly longer duration of
pain relief, lower narcotic requirement, and less
likely to have severe pain at death. Scores for
disability and mood progressively worsened over
the clinical course of disease for all patients. No
significant difference was found in mood and
disability score between the alcohol and control
group. Survival was found to be markedly
improved in alcohol group when compared to
control group (p<0.0001).

There were two cases with
transient episodes of hypertension
without sequelae during
alcohol injection. There was no
complication associated with
hypotension or bleeding following
any celiac plexus injection.

Intraoperative chemical
splanchniectomy with
alcohol should be
advocated for all patients
with unresectable
pancreatic cancer.

Kawamata et
al., 199654.

Randomized
controlled trial

Patients with
advanced
pancreatic cancer

21

NCPB vs. SAT

VAS pain score,
morphine
consumption,
performance
status, and selfassessed QoL
scores

15-20 ml of 80%
alcohol bilaterally

VAS score was significantly lower for the first
4 weeks after NCPB compared to NSAIDMorphine treatment. Morphine consumption was
found to be significantly lower in NCPB group
than those in NSAID-morphine group at 4-7
weeks post-procedure. Statistically significant
improvement in performance status was found
only at 4th week between the two groups.

Symptoms of loss of appetite
at 6th and 8th week and nausea
at 8th week were found to be
significantly higher in NSAIDmorphine group.

Improvement in pain
management may not
correlate with better
quality of life in advanced
pancreatic cancer patients.

Polati et al.,
199855.

Prospective,
randomized
double-blind
trial

Patients with
unresectable
pancreatic
adenocarcinoma

24

NCPB vs. SAT

VAS pain
score, mean
consumption
of diclofenac
sodium and
opioids

7 ml of absolute
alcohol via each
needle

Primary endpoint was immediate (24-48 h) and
long-term efficacy of the treatment until death.
Complete pain relief at 24- and 48-h interval was
reported in 9 out of 12 patients in NCPB group
but only 2 out of 12 patients in pharmacological
therapy group. However, long-term pain relief
was not significant between the two groups.
Mean consumption of NSAID and opioid was
significantly lower in NCPB group

Transient diarrhea and orthostatic
hypotension were observed in 3
and 5 patients who underwent
NCPB, respectively.

Neurolytic celiac plexus
block can abolish visceral
celiac type of cancerrelated pain in a significant
portion of pancreatic cancer
patients. It also reduces the
incidence of drug-related
adverse events due to lower
opioid consumption.

Staats et al.,
200174.

Prospective,
randomized,
double-blind,
controlled trial

Patients with
unresectable
pancreatic cancer

139

Chemical
splanchniectomy
with 50% alcohol
in saline vs. 0.9%
normal saline
injection during
surgical exploration

VAS pain
score, mood
score, pain
interference
with activities
of daily living,
survival rate

20 ml of 50%
alcohol bilaterally

There was significant reduction in VAS pain
score in alcohol group compared to saline
group. Alcohol block also significantly improved
longevity compared to saline block. High
negative mood patients were correlated to
more pain interference with daily activities.
Postoperative pain score was found to be
inversely correlated with longevity, and the
correlation was significant.

N/A

Bilateral splanchniectomy
with alcohol during surgical
laparotomy improved
pain, mood, activities, and
longevity in pancreatic
cancer patients.

Özyalçin et
al., 200471.

Prospective,
single blind,
randomized
trial

Pancreatic
cancer patients
with tumor
involvement of
body and/or tail of
pancreas

39

Celiac plexus block
vs. splanchnic
nerve block

VAS pain
score, opioid
consumption,
QoL, survival
rate

40 ml of 75%
ethanol for NCPB
and 6 ml of 75%
ethanol for bilateral
splanchnic nerve
blockade

Splanchnic nerve block provided significantly
greater VAS difference, lower opioid
requirement, and greater survival rate than
celiac plexus block. However, QoL was found to
be insignificant between the two groups.

Two patients in celiac group and
one patient in splanchnic group
reported severe pain during
procedure. Five patients in
celiac group developed transient
diarrhea. Two patients in celiac
group required inotropic support
for hemodynamic instability.

Splanchnic nerve blockade
may be more effective than
celiac plexus blockade in
patients with advanced
cancer with tumor involving
the pancreatic body and tail.

Wong et al.,
200456.

Prospective,
double-blind,
randomized
controlled trial

Patients with
unresectable
pancreatic cancer

100

NCPB vs. SAT

NRS pain
score, opioid
consumption,
QoL, survival
time

10 ml of absolute
alcohol via each
needle

Mean pain intensity was significantly reduced in
both groups as early as 1 week after treatment.
The reduction in pain was significantly greater in
NCPB than SAT group. QoL gradually declined
after one-week post-treatment in both groups
with no significant difference between the two
groups. Opioid consumption increased over
time with no difference between the two groups.
No significant difference in survival was found
between treatment groups.

N/A

NCPB improves pain relief
in patients with pancreatic
cancer compared to SAT
but not QoL and survival.

Jain et al.,
200557.

Prospective
controlled trial

Patients with
advanced upper
abdominal
malignancies

100

NCPB vs. SAT

VAS pain score,
morphine
consumption,
QoL

20 ml of 50%
alcohol

VAS score was significantly lower in NCPB
group than that of control group at 7 and 30
days after treatment. Morphine consumption was
significantly lower in NCPB group compared to
that of control group at 30 days after treatment.
Quality of life was significantly improved in
NCPB group but not statistically different from
control group at 30 days.

Celiac plexus neurolysis
statistically lowers pain intensity,
reduces morphine consumption,
and improves QoL at 30-day
interval, but there was no
significant difference in QoL when
compared with morphine group

Side effects of treatment
were significantly higher in
morphine group.

Zhang et al.,
200858.

Prospective
randomized
controlled
study

Patients with
unresectable
pancreatic cancer

56

CT-guided NCPB
vs. SAT

VAS pain
score, opioid
consumption,
QoL

20 ml of absolute
alcohol

Patients who underwent NCPB had significantly
lower VAS pain score than those at 1, 7, and
14 days. Opioid consumption was significantly
lower in NCPB than control group at day 7,
14, 30, 60, and 90 days. Quality of life was
significantly improved after treatment, but no
significant difference was found between the
two groups.

Orthostatic hypotension,
drunkenness symptoms, diarrhea,
and burning pain at needle entry
site were reported. Only 6 patients
who underwent NCPB had
nausea and vomiting compared to
22 patients in control group, which
was significantly different.

CT-guided NCPB is safe
and effective modality for
cancer-related pain relief in
advanced pancreatic cancer
patients.

VAS – Visual Analog Scale; NRS – Numeric Rating Scale; NCPB – Neurolytic Celiac Plexus Block; SAT – Systemic Analgesic Therapy; QoL – Quality of Life; NSAID – nonsteroidal anti-inflammatory drug;
CT – Computed Tomography; N/A – not applicable
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the inter-patient discrepancy between partial
and complete pain relief could be multi-fold
and possibly related to incomplete destruction
of the celiac plexus. As demonstrated by
postmortem neurohistological studies of the
celiac plexus, evidence of perineural fibrosis,
shrunken-looking neurons, normal-appearing
nerve fibers, and lymphocytes in pancreatic
cancer patients after NCPB implied the
very common nature of incomplete celiac
neurolysis.60 Other proposed theories
included the coexistence of more than
one source of pain, insufficient spread of
neurolytic agent, and migration of tumor cells
into surrounding tissues.51
One multi-centered study prospectively
examined the predictors of successful
response to NCPB in 22 patients with
pancreatic cancer pain. Mercadante and
associates concluded that the experience
of the physician and local spread of the
tumor are likely the predominant factors
contributing to the outcomes of NCPB.61
Unsatisfactory responses to repeated trials
of NCPB have also been demonstrated
by CT in patients with massive invasion
and metastases around the celiac axis.62 A
pilot study conducted by McGreevy et al.
also confirmed the significance of disease
progression and metastases in predicting the
outcome for repeat NCPB.63 De Cicco et al.
divided the celiac axis into four quadrants and
demonstrated that only complete neurolytic
spread of all four quadrants could guarantee
long-lasting analgesia, indicating the clinical
significance of injectate spread for predicting
the efficacy of NCPB.64 Furthermore,
Rykowski et al. revealed that the location
of the pancreatic tumor was an independent
prognostic factor for predicting the efficacy
of NCPB. Of the 37 patients (74%) who
responded favorably to NCPB, 33 patients
had a tumor involving the head of pancreas
and four patients had a tumor involving
the body and tail of the pancreas.62 Their
findings suggested that the location of tumor
involvement in the pancreas correlates to
disease progression and alters the efficacy of
NCPB.
It is interesting to note that regardless of
whether radiographic guidance was used
for NCPB, Eisenberg et al. reported no
difference in the rate of successful blockade
and incidence of adverse events.59 Similarly,
McGreevy et al. compared CT-guided to
fluoroscopy-guided NCPB and reported no
significant difference between responders
and non-responders to repeat NCPB.63
However, Erdek et al. found that NCPB with
CT-guidance was correlated with positive
outcomes, but the results were marginally
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significant (p < 0.06).65 Compared to
fluoroscopy, CT provides images with higher
spatial resolution and thereby enhances
visualization of the celiac ganglia, tumor
burden, and needle position. Despite higher
radiation exposure from CT, these advantages
assuredly attribute to the higher likelihood
of achieving superior analgesia from NCPB.
Overall, Eisenberg et al. concluded that NCPB
is a relatively safe intervention for short- and
long-term palliation of cancer-related pain in
patients with intraabdominal malignancies.
A 2007 review by Yan and Myers included
302 patients from 5 RCTs conducted during
the period extending from 1966 to 2005.66
The authors found only 6% reduction in
pain intensity from NCPB compared to
baseline pain score. Nevertheless, there was
a significant mean reduction of 40 to 80 mg
daily dose of opioid in NCPB compared to
SAT at two, four and eight weeks, which
was based on data extracted from three
studies.52,54,56 Similar to Eisenberg et al.,
the authors concluded that NCPB is a safe
technique to be incorporated in the standard
treatment of patients with inoperable
pancreatic cancer for effective reduction
in pain intensity, analgesic requirements,
and opioid-induced constipation.66 Another
systematic review by Moor and Adler was
performed in 2009.67 However, no literature
search criteria were described for the selection
of appropriate studies. Regardless, they also
concluded that NCPB is a safe technique that
provides long-lasting, opioid-sparing benefits
in pancreatic cancer patients.
A Cochrane Review by Arcidiacono et al.
evaluated 358 participants included in six
RCTs.68 There was profound reduction in
opioid consumption, lower incidence of
diarrhea or constipation, and improvement in
immediate pain relief with a weighted mean
difference of -0.42 at four weeks between
NCPB and SAT groups (p = 0.004). Despite
the lack of strong evidence supporting the
therapeutic superiority of NCPB over SAT
in pancreatic cancer patients, the authors
highlighted the clinical significance of
incorporating NCPB as an opioid-sparing
strategy to abate opioid-related adverse
effects.
A systematic review by Nagels et al. identified
five RCTs, which included results for 295
patients.69 The meta-analysis demonstrated
significant differences of -0.87 and -0.47
in pain reduction when NCPB (n = 149)
was compared to SAT (n = 146) at one to
two weeks (p = 0.004) and four weeks (p =
0.0001), respectively. However, significant
differences in pain intensity between the two

groups dissipated at 8 (p = 0.16) and 12 weeks
in four and two relevant studies, respectively.
Both NCPB and SAT groups exhibited
significant reduction of opioid consumption
compared to baseline. Significant difference
in the reduction of opioid consumption was
also found between the two groups at all of
the time intervals. The mean difference in
morphine usage was reported to be -44.64
at one to two weeks (p = 0.002), -72.41 at
4 weeks (p < 0.00001), and -65.69 at eight
weeks (p < 0.0001). Only one study had
data available at 12 weeks, which reported a
significantly lower consumption of morphine
in NCPB group compared to SAT group (105
± 65 mg vs. 169 ± 71 mg; p < 0.01). The
authors concluded that percutaneous NCPB
is safe and capable of delivering superior
analgesic benefits to patients with advanced
upper intra-abdominal cancer.
Another meta-analysis by Zhong et al.
examined 7 RCTs, which included 196
patients who met eligibility criteria.70 Among
the four studies with the assessment of pain
score at four weeks, there was a statistically
significant mean difference in pain score of
-0.382 between NCPB (n = 99) and SAT (n
= 98) (p = 0.005). At 8 weeks, the statistical
significance of mean difference in pain
score between NCPB (n = 184) and SAT
(n = 195) was no longer maintained based
on 6 relevant studies. Regarding the use of
pharmacological analgesics, there was a mean
difference of -49.77 (p = 0.005) and -48.29
(p < 0.001) between NCPB and SAT groups
at four weeks and one day before death,
respectively, based on five relevant studies.
Of the studies included in this meta-analysis,
NCPB was performed by percutaneous
NCPB, EUS-guided NCPB, thoracoscopic
splanchniectomy, and intraoperative
chemical splanchniectomy. The impact of
these approaches to performing NCPB on
the efficacy of pain relief remains largely
unknown due to the dearth of comparative
studies among these interventions.69 In
summary, albeit concerns about the potential
effects of confounding bias, this systematic
review demonstrated statistically significant
short-term (four weeks) efficacy of NCPB in
cancer-related pain and that the efficacy was
further supported by significantly decreased
consumption of opioid and NSAIDs.69,70
Efficacy of Celiac Plexus Neurolysis vs.
Splanchnic Nerve Neurolysis
Innervations of the upper abdominal viscera
are mediated by sensory afferent and
sympathetic efferent fibers via the splanchnic
nerves and celiac ganglia.23 Theoretically,
blockade of either the celiac ganglia or
splanchnic nerves will deter nociceptive
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transmission of the upper abdominal viscera.
A total of two prospective, randomized,
comparative studies of percutaneous celiac
plexus and splanchnic nerve blockade on the
efficacy of cancer-related pain relief were
found in the literature. Ischia and colleagues
explored the efficacy of percutaneous NCPB
using three different techniques, namely,
transaortic celiac plexus block, classic
retrocrural block, and bilateral chemical
splanchiectomy on pain relief. They found no
significant difference in pain reduction among
the three techniques.51
Özyalçin and colleagues conducted a
comparative study on the efficacy of celiac
plexus and splanchnic nerve blockades in
pancreatic cancer patients.71 This prospective,
single-blinded, randomized study enrolled
39 patients with pancreatic adenocarcinoma.
Patients who received bilateral splanchnic
nerve blockade reported a significantly greater
VAS pain score reduction than those with
celiac plexus blockade up to 12-weeks after
intervention (p ≤ 0.002). These patients also
had a more substantial decrease in total daily
codeine requirement up to 10 weeks after
treatment (p ≤ 0.041) and increase in survival
rate (p = 0.0072). Surprisingly, no difference
in QoL was clinically observed between celiac
and splanchnic nerve blocks. The authors
concluded that splanchnic nerve blocks may
be a viable alternative to celiac plexus block
based on statistically better outcomes in pain
reduction, opioid usage and longevity. These
two small, but otherwise good quality trials
did not provide sufficient evidence that celiac
plexus and splanchnic nerve neurolysis differ
in their relative efficacy.
Effect of Celiac Plexus Neurolysis on Quality
of Life and Survival
Despite the clinical benefit in the palliation
of cancer-related pain, the effect of NCPB on
QoL and survival in patients with advanced
intraabdominal malignancies remains largely
controversial. Kawamata et al. performed a
pilot study comparing NCPB with SAT on the
effect of QoL.54 Despite profound reduction
in pain and opioid consumption in NCPB
group, QoL only improved at the two-week
interval. Gradual deterioration in QoL was
observed over time with disease progression.
We can infer that pain severity and opioid
use do not wholly contribute to QoL, which
can also be influenced by physiological
variables, symptom status, functional health
and general health perceptions.72 Both Jain et
al. and Zhang et al. found that as an effective
analgesic intervention, NCPB provided no
significant difference in improving QoL
compared to opioids alone.57,58 Despite these
discouraging outcomes, most practitioners
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remain inclined to attribute the experience of
suboptimal pain control to deleterious effects
on all aspects of QoL in cancer patients of all
stages.
Cancer-related pain is a common and highly
debilitating symptom associated with
functional, cognitive, and psychological
impairments.3,73 Theoretically, optimal
pain control should promote restoration of
physical well-being and functional capacity
in cancer patients. With less psychological
distress, fatigue, and functional impairment,
cancer patients can undergo therapies to ease
symptoms and prolong survival.73 Ischia and
colleagues found no significant difference in
survival times in 61 patients with unresectable
pancreatic cancer after NCPB.51 Surprisingly,
Lillemoe et al. evaluated 137 patients and
found that survival was markedly improved
with alcohol splanchniectomy compared to
those in the saline group (p < 0.0001).53 Staats
et al. completed a randomized control trial
involving 139 participants with unresectable
pancreatic cancer.74 Among 130 patients
who completed the study, it was noted that
NCPB with alcohol during laparotomy had
a significantly positive impact on longevity
compared to those with saline (p < 0.01).
The study also found a negative correlation
between post-procedural cancer-related pain
and survival. The authors postulated that
improved survival might be attributed to
better QoL including better sleep quality and
appetite, improved mood, enhanced functional
capacity and reduced risks of thrombotic
events.
Despite the encouraging outcomes on
longevity by Staat et al. and Lillemoe et al.,
Wong and colleagues conducted a randomized
control trial with contradictory findings.56
Their study evaluated the effect of NCPB on
pain relief, QoL, and survival in 100 patients
with unresectable pancreatic cancer. Despite
significant short-term pain reduction, NCPB
did not offer significant benefits on either QoL
(p = 0.46) or survival (p = 0.26) within the
12-week follow-up period. QoL was found to
gradually decrease with time. By the end of
the double-blind phase, only 16% of NCPB
patients and 6% of SAT patients remained
alive, with no significant difference in survival
rate between the two groups, implying the
lack of correlation between pain reduction and
survival.
Özyalçin and colleagues compared the
analgesic efficacy of celiac plexus block
and splanchnic nerve block and reported
no significant difference in QoL between
the two groups on the basis of performance
status and patient satisfaction.71 Interestingly,

patients with tumor involving the body and/
or tail of pancreas who underwent splanchnic
nerve blockade had significantly higher mean
survival rate (68.85 ± SE 7.3 days) than
those who underwent celiac plexus blockade
(45.37 ± SE 5.82 days; p = 0.0072). The
results implied that greater pain reduction,
lower opioid consumption and longer lifeexpectancy in the splanchnic group may be
independent of QoL.
In a systematic review by Yan and Myers, the
evidence did not support any clinical benefits
in survival rates and QoL despite better pain
control and less opioid use from NCPB.66 In
a more recent systematic review by Nagels,69
improved QoL score from baseline was
detected initially in two relevant studies but
deteriorated gradually over time with disease
progression.54,71 None of the RCTs exhibited
any significant difference in QoL between
percutaneous NCPB and SAT.
Overall, NCPB has not convincingly
been demonstrated to improve QoL and
prolong survival in patients with upper
intra-abdominal malignancies. These
findings may be due to tumor progression
in advanced disease. A recent preclinical
study has provided insights into the basis
of neural-tumor interactions. Saloman et al.
demonstrated that sensory neuron ablation
by injection of capsaicin in two mouse
models of pancreatic ductal adenocarcinoma
prevented neurogenic inflammation,
delayed tumor progression and significantly
prolonged survival (7.80 vs. 4.53 months,
p = 0.0001).75 Denervation of primary
afferents that innervate the pancreas can block
perineural invasion, astrocyte activation and
neuronal damage, resulting in suppression of
tumorigenesis in early stages of pancreatic
cancer.76 These experimental findings support
the clinical significance of NCPB in the
early stages of pancreatic cancer to prolong
survival, and explain the minimal benefits on
overall survival in patients with inoperable
pancreatic cancer.
Volume of Neurolytic Agents in Celiac Plexus
Blockade
Neurolytic agents, especially alcohol, have
been described to cause neural destruction of
the celiac/splanchnic plexus for pain relief in
cancer patients. However, optimal volume of
neurolytic agent remains to be established.
In clinical practice, administration of 10-80
ml of alcohol has been cited for NCPB, with
typical volumes ranging from 20 to 40 ml.77,78
Within the literature, there is only one RCT
exploring the effect of different volumes of
alcohol on cancer-related pain reduction.79
Dolly and colleagues selected 30 patients with
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upper abdominal malignancies as candidates
for NCPB. The results showed that 20, 30,
and 40 ml of 70% alcohol provided a duration
of blockade lasting eight, 12, and 16 weeks,
respectively. Forty mililiters of injectate was
found to have a significantly lower morphine
requirement and higher QoL scores compared
to 20 and 30 ml. These outcomes validated
the rationale proposed by De Cicco et al. that
thorough spread of alcohol, involving all four
quadrants of the celiac axis, was essential
to achieve complete pain relief.64 Therefore,
the possibility of volume to affect the spread
of neurolytic agent is certainly plausible for
predicting the outcome in pain reduction,
analgesic usage and QoL. Given the paucity
of studies further large-scale randomized trials
are needed to address the optimal volume of
neurolytic agent to administer during NCPB.
Types of Neurolytic agents in Celiac Plexus
Blockade
Neurolytic agents such as phenol and
alcohol have been used extensively to induce
disintegrative nerve changes via Wallerian
degeneration, promoting long-lasting
analgesia, reportedly up to six months.80,81,82,83
The extent and duration of analgesia after
ablation are frequently limited by axonal
regeneration, which begins within three
to six months at a rate of 1 to 1.5 mm per
week.80,81,82,83,84 Concentrations of 50-100%
alcohol and 6-10% phenol have been used
successfully for chemical ablation of neural
structures.24,85 Koyyalagunta and colleagues
retrospectively evaluated 93 patients with
abdominal cancer pain.86 The authors found
no significant difference in pain reduction
at one month between alcohol and phenol
use for NCPB (p = 0.66). There was also
no difference in complications between the
two agents. The authors demonstrated that
both neurolytic agents were equally effective
and safe for cancer-related pain relief. With
limited evidence, prospective randomized
studies are needed to validate that both
alcohol and phenol are equally effective in
NCPB.
Safety of Celiac Plexus Neurolysis
Eisenberg et al. reported that adverse events
including local pain (96%), diarrhea (44%),
and hypotension (38%) were common but
transient, self-limited and of mild severity.59
Severe neurological complications accounted
for an estimated incidence of 1% and included
lower extremity weakness, paresthesia,
epidural anesthesia and lumbar puncture.
Other non-neurological complications
accounted for an additional 1%. These
included pneumothorax, shoulder, chest and
pleuritic pain, hiccoughing and hematuria.

Dec. 2020 | Vol. 2 | Issue 2

Yan and Myers found no significant difference
in nausea, vomiting, diarrhea and sedation
among treatment groups, but constipation was
significantly less in NCPB group.66 Orthostatic
hypotension was more common in the NCPB
group, but the difference between treatment
groups was not statistically significant (p =
0.09).
Recently, a meta-analysis was performed for
analyzing diarrhea, constipation, hypotension,
and nausea and vomiting for percutaneous
NCPB.69 The incidence of diarrhea (p =
0.0003) and hypotension (p = 0.0003) were
significantly higher in NCPB than SAT. The
results were not surprising as sympatholytic
agents were known to cause hypotension.
Diarrhea was common due to unopposed
stimulation of the parasympathetic nervous
system.86 Conversely, the incidence of
constipation, nausea and vomiting were
significantly lower in NCPB than SAT (p <
0.0001), suggesting opioid-sparing effect of
NCPB.66
Other less common side effects included local
pain at needle puncture site (7-29%), back
pain (5-60%), shoulder pain (6-9%), signs of
alcohol intoxication (7-22.4%), pneumothorax
(1-3%), reactive pleurisy or pleural effusion
(5-8%), transient dysesthesias (0.3-7%),
transient neuritis (2-37%), permanent
foot drop (1.5%), transient monoparesis
(0.3%), peritonitis (6%) and hematuria (<26%)66. Permanent, partially reversible and
completely reversible paraplegia have also
been reported.66
Davies conducted a survey of 160 pain
clinics in England and Wales that performed
NCPB over a 5 year period (1986-1990)
They noted that 4 out of 2730 NCPB
patients developed permanent paraplegia.87
Postulated mechanisms for the resulting
paraplegia included inadvertent seepage
or injection of neurolytic agent into the
cerebrospinal fluid and impaired blood supply
to the spinal cord due to injury or spasm of
the artery of Adamkiewicz. The estimated
incidence of permanent paraplegia accounted
for approximately 0.15%. Other rare
complications such as sexual dysfunction,88
retroperitoneal hematoma,89 abdominal aortic
dissection,90 chylothorax,91 diaphragmatic
paralysis,92 and hemorrhagic gastritis and
duodenitis93 had all been reported. Despite
considerable risks of major complications,
NCPB is widely considered to be a safe
procedure because operative mortality
and catastrophic complications remain
exceedingly rare.

Conclusion
Neurolytic blockade of the celiac/splanchnic
plexus can be used safely in cancer patients
for analgesic control. It provides superior
pain control and an analgesic-sparing effect
in patients with advanced intraabdominal
malignancies up to six months, particularly
when combined with SAT. At the present
time, the data concerning NCPB for improved
survival and QoL are inconsistent and less
compelling. There is also no evidence of
superiority for neurolysis of celiac plexus
or splanchnic nerves. Predictive factors
contributing to the efficacy of NCPB include
disease progression, metastases, operator
experience, location of tumor, tumor burden
and injectate spread. The use of alcohol and
phenol appear to be equally effective for
cancer-related pain relief. The optimal volume
of neurolytic agent remains controversial, but
40 ml of alcohol appears to yield adequate
extent of longitudinal spread along the celiac
axis. We conclude that early application of
NCPB should be encouraged to serve as
a supplement to multimodal analgesia for
malignant pain in patients with advanced
disease. The decision to employ NCPB should
always be individualized, by incorporating
patients’ preferences and weighing the risk/
benefit profiles. 
https://doi.org/10.32873/unmc.dc.gmerj.2.2.005
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